Cassava Sciences, Inc. (SAVA): Price and Financial Metrics


Cassava Sciences, Inc. (SAVA): $30.44

-0.36 (-1.17%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SAVA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SAVA Stock Price Chart Interactive Chart >

Price chart for SAVA

SAVA Price/Volume Stats

Current price $30.44 52-week high $146.16
Prev. close $30.80 52-week low $15.72
Day low $29.42 Volume 1,219,700
Day high $31.57 Avg. volume 1,685,148
50-day MA $24.07 Dividend yield N/A
200-day MA $41.45 Market Cap 1.22B

Cassava Sciences, Inc. (SAVA) Company Bio


Cassava Sciences, Inc. develops drugs using its proprietary technology. The Company develops safer and efficacious drugs for use in pain management, particularly in the area of opioid painkillers. Cassava Sciences has products in clinical trials.


SAVA Latest News Stream


Event/Time News Detail
Loading, please wait...

SAVA Latest Social Stream


Loading social stream, please wait...

View Full SAVA Social Stream

Latest SAVA News From Around the Web

Below are the latest news stories about Cassava Sciences Inc that investors may wish to consider to help them evaluate SAVA as an investment opportunity.

10 Most Shorted Stocks Right Now

In this article, we discuss the 10 most shorted stocks right now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Most Shorted Stocks Right Now. The beginning of 2021 had pitted retail investors against hedge funds in a short squeeze saga involving video game firm GameStop and […]

Yahoo | February 18, 2022

We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Yahoo | February 17, 2022

Cassava Sciences: Enormous Upside If Pipeline Is Successful

I am neutral on Cassava Sciences (SAVA) as it has enormous upside potential if it can successfully develop its pipeline, Wall Street analysts are unanimously bullish on it, and the average price target implies it could triple over the next year. On the other hand, the company is not yet profitable and remains highly speculative. Cassava Sciences was formed in 1998, and it is headquartered in Texas, United States. The company operates as a clinical-stage biotechnology company in the industry, with a primary focus on neurodegenerative diseases, such as Alzheimer's.

Samuel Smith on TipRanks | February 15, 2022

Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know

Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $49.22, moving +1.07% from the previous trading session.

Yahoo | February 15, 2022

Cassava Sciences (SAVA) Receives a Buy from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Buy rating on Cassava Sciences (SAVA – Research Report) yesterday and set a price target of $110.00. The company's shares closed last Friday at $49.59, close to its 52-week low of $31.44. According to TipRanks.com, McCarthy has 0 stars on 0-5 stars ranking scale with an average return of -23.3% and a 18.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cassava Sciences with a $102.

Howard Kim on TipRanks | February 11, 2022

Read More 'SAVA' Stories Here

SAVA Price Returns

1-mo 14.18%
3-mo -24.17%
6-mo -31.60%
1-year -61.18%
3-year 2,415.70%
5-year 637.05%
YTD -30.34%
2021 540.76%
2020 31.15%
2019 511.76%
2018 -78.75%
2017 0.25%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5318 seconds.